LDL Specific Neutra™ Antibody Products

Are lengthy drug development cycles or challenges in generating high-affinity antibodies hindering your cardiovascular research? Creative Biolabs' LDL-specific neutra™ antibody products leverage advanced recombinant protein engineering and rigorous validation protocols to deliver highly specific neutralizing antibodies, streamlining therapeutic development and clinical translation.

Introduction to LDL

Low-density lipoprotein (LDL), a lipid-protein complex, transports cholesterol from the liver to peripheral tissues. While essential for cellular membrane synthesis and hormone production, elevated LDL levels drive arterial plaque formation, establishing it as a primary biomarker for cardiovascular disease risk.

Fig. 1 Metabolism of LDL.¹

• Structural Complexity

LDL particles comprise a hydrophobic core of cholesterol esters and triglycerides encased in a monolayer of phospholipids and apolipoprotein B-100 (ApoB-100). The ApoB-100 moiety mediates binding to the LDL receptor (LDLR), enabling cellular uptake. Small, dense LDL (sdLDL) subfractions exhibit heightened atherogenicity due to prolonged circulation and increased oxidative susceptibility.

• Pathogenic Signaling Pathways

Oxidized LDL (oxLDL) activates endothelial cells and macrophages via scavenger receptors (e.g., LOX-1, CD36), triggering foam cell formation and pro-inflammatory cytokine release (e.g., IL-6, TNF-α). This cascade promotes NF-κB-driven vascular inflammation and smooth muscle cell proliferation, accelerating atherosclerosis. Additionally, oxLDL inhibits endothelial nitric oxide synthase (eNOS), impairing vasodilation and exacerbating cardiovascular dysfunction.

• Associated Pathologies

Hypercholesterolemia, characterized by elevated LDL levels, is a modifiable risk factor for atherosclerosis, coronary artery disease (CAD), and ischemic stroke. Genetic disorders like familial hypercholesterolemia (FH) highlight the critical role of LDLR and ApoB-100 in LDL metabolism, underscoring the therapeutic value of targeting LDL.

Applications of LDL-Neutralizing Antibodies

• Atherosclerosis Therapeutics

Neutralizing antibodies that bind oxLDL or ApoB-100 prevent LDL retention in arterial walls, reducing foam cell formation. In vivo studies demonstrate significant plaque regression in animal models, supporting their potential as monoclonal antibody (mAb)-based therapies for CAD.

• Diagnostic Biomarker Development

High-specificity Anti-LDL antibodies enable precise quantification of LDL subfractions in clinical assays. These tools enhance risk stratification by identifying patients with elevated sdLDL, a predictor of cardiovascular events.

• Combinatorial Therapeutic Strategies

Anti-LDL antibodies synergize Satins or PCSK9 inhibitors to amplify LDL clearance. This approach addresses statin resistance in FH patients, offering a multi-target strategy for refractory hypercholesterolemia.

• Vaccine Development

Antibodies targeting immunogenic LDL epitopes are being explored as vaccines to induce endogenous neutralizing antibodies, offering long-term LDL management with reduced dosing frequency.

Our Anti-LDL Recombinant Antibody Products

Neutralizing antibodies against LDL focus on blocking ApoB-100 epitopes or binding oxLDL-specific oxidized phospholipids. Creative Biolabs has developed anti-LDL antibodies that exhibited high affinity for conformational epitopes on LDL particles, inhibiting LDLR-mediated uptake or enhancing macrophage-mediated clearance. Validated in preclinical models, these antibodies reduce plaque burden and improve lipid profiles. Applications extend to diagnostics, such as quantifying LDL subfractions in serum via ELISA, and therapeutics, including antibody-drug conjugates for targeted lipid-lowering therapies.

Creative Biolabs' LDL-specific neutra™ antibody products are rigorously validated for specificity and performance in research applications. Engineered to meet the demands of cardiovascular research, our antibodies empower breakthroughs in lipid metabolism studies and drug development. Contact our scientific team today to explore how our anti-LDL antibodies can advance your projects.

REFERENCE

1. Qiao, Ya-Nan, Yan-Li Zou, and Shou-Dong Guo. "Low-density lipoprotein particles in atherosclerosis." Frontiers in Physiology 13 (2022): 931931. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fphys.2022.931931